# Arnaud Scherpereel

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/arnaud-scherpereel/

## Facts

| Field | Value |
| --- | --- |
| Citations | 19,026 |
| Field | Occupational and environmental lung diseases |
| h-index | 66 |
| i10-index | 173 |
| Last Known Institution | Inserm |
| OpenAlex ID | https://openalex.org/A5089982794 |
| ORCID iD | https://orcid.org/0000-0002-7607-1863 |
| Works | 463 |

## Researcher papers

- [First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial](https://scholariq.org/papers/first-line-nivolumab-plus-ipilimumab-in-unresectable-malignant-pleural/)
- [Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/bevacizumab-for-newly-diagnosed-pleural-mesothelioma-in-the-mesothelioma-avastin/)
- [Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)](https://scholariq.org/papers/updated-overall-survival-and-pd-l1-subgroup-analysis-of-patients-with-extensive/)
- [Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer](https://scholariq.org/papers/intestinal-akkermansia-muciniphila-predicts-clinical-response-to-pd-1-blockade/)
- [Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial](https://scholariq.org/papers/nivolumab-or-nivolumab-plus-ipilimumab-in-patients-with-relapsed-malignant/)
- [First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743](https://scholariq.org/papers/first-line-nivolumab-plus-ipilimumab-versus-chemotherapy-in-patients-with/)

## Researcher topics

- [Occupational and environmental lung diseases](https://scholariq.org/topics/occupational-and-environmental-lung-diseases/)
- [Pleural and Pulmonary Diseases](https://scholariq.org/topics/pleural-and-pulmonary-diseases/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Researcher university

- [Inserm](https://scholariq.org/institutions/inserm/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.